{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:04:22Z","timestamp":1787061862502,"version":"build-2736575974"},"reference-count":100,"publisher":"Bentham Science Publishers Ltd.","issue":"6","funder":[{"DOI":"10.13039\/501100001807","name":"FAPESP, Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["13\/07600-3"],"award-info":[{"award-number":["13\/07600-3"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Alzheimer's disease (AD) is a chronic neurodegenerative disease\nand the most common form of dementia, especially in the elderly. Due to the increase in\nlife expectancy, in recent years, there has been an excessive growth in the number of people\naffected by this disease, causing serious problems for health systems. In recent years,\nresearch has been intensified to find new therapeutic approaches that prevent the progression\nof the disease. In this sense, recent studies indicate that the dual-specificity tyrosine\nphosphorylation regulated kinase 1A (DYRK1A) gene, which is located on chromosome\n21q22.2 and overexpressed in Down syndrome (DS), may play a significant role in developmental\nbrain disorders and early onset neurodegeneration, neuronal loss and dementia\nin DS and AD. Inhibiting DYRK1A may serve to stop the phenotypic effects of its overexpression\nand, therefore, is a potential treatment strategy for the prevention of ageassociated\nneurodegeneration, including Alzheimer-type pathology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>In this review, we investigate the contribution of DYRK1A inhibitors as potential\nanti-AD agents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A search in the literature to compile an in vitro dataset including IC50 values involving\nDYRK1A was performed from 2014 to the present day. In addition, we carried\nout structure-activity relationship studies based on in vitro and in silico data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>molecular modeling and enzyme kinetics studies indicate that DYRK1A may\ncontribute to AD pathology through its proteolytic process, reducing its kinase specificity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>further evaluation of DYRK1A inhibitors may contribute to new therapeutic\napproaches for AD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0929867329666220620162018","type":"journal-article","created":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T02:44:23Z","timestamp":1655779463000},"page":"669-688","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["DYRK1A Inhibitors and Perspectives for the Treatment of Alzheimer's\nDisease"],"prefix":"10.2174","volume":"30","author":[{"given":"M\u00e1rcia Maria","family":"de Souza","sequence":"first","affiliation":[{"name":"School of Health Sciences, Graduate Program in Pharmaceutical Sciences, UNIVALI, Rua Uruguai, 458 F6 lab 206 Campus I, Centro, Itajai, SC, 88302-202, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur Ribeiro","family":"Cenci","sequence":"additional","affiliation":[{"name":"Department of Exact Sciences and Education, Federal University of Santa Catarina, R. Jo\u00e3o Pessoa, 2750 - Velha, 89036-002, Blumenau, SC, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerolain Faoro","family":"Teixeira","sequence":"additional","affiliation":[{"name":"Department of Exact Sciences and Education, Federal University of Santa Catarina, R. Jo\u00e3o Pessoa, 2750 - Velha, 89036-002, Blumenau, SC, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valkiria","family":"Machado","sequence":"additional","affiliation":[{"name":"Department of Exact Sciences and Education, Federal University of Santa Catarina, R. Jo\u00e3o Pessoa, 2750 - Velha, 89036-002, Blumenau, SC, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majory Christina Garcia","family":"Mendes Schuler","sequence":"additional","affiliation":[{"name":"Department of Exact Sciences and Education, Federal University of Santa Catarina, R. Jo\u00e3o Pessoa, 2750 - Velha, 89036-002, Blumenau, SC, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Elisa","family":"Gon\u00e7alves","sequence":"additional","affiliation":[{"name":"School of Health Sciences, Graduate Program in Pharmaceutical Sciences, UNIVALI, Rua Uruguai, 458 F6 lab 206 Campus I, Centro, Itajai, SC, 88302-202, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Paula Dalmagro","sequence":"additional","affiliation":[{"name":"School of Health Sciences, Graduate Program in Pharmaceutical Sciences, UNIVALI, Rua Uruguai, 458 F6 lab 206 Campus I, Centro, Itajai, SC, 88302-202, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila","family":"Andr\u00e9 Cazarin","sequence":"additional","affiliation":[{"name":"School of Health Sciences, Graduate Program in Pharmaceutical Sciences, UNIVALI, Rua Uruguai, 458 F6 lab 206 Campus I, Centro, Itajai, SC, 88302-202, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo Luiz","family":"Gomes Ferreira","sequence":"additional","affiliation":[{"name":"Laboratory of Medicinal and Computational Chemistry, Center for Research and Innovation in Biodiversity and Drug Discovery, Institute of Physics of S\u00e3o Carlos, University of S\u00e3o Paulo, S\u00e3o Carlos-SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldo Sena","family":"de Oliveira","sequence":"additional","affiliation":[{"name":"Laboratory of Medicinal and Computational Chemistry, Center for Research and Innovation in Biodiversity and Drug Discovery, Institute of Physics of S\u00e3o Carlos, University of S\u00e3o Paulo, S\u00e3o Carlos-SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriano Defini","family":"Andricopulo","sequence":"additional","affiliation":[{"name":"Laboratory of Medicinal and Computational Chemistry, Center for Research and Innovation in Biodiversity and Drug Discovery, Institute of Physics of S\u00e3o Carlos, University of S\u00e3o Paulo, S\u00e3o Carlos-SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1002\/iub.2057","volume":"71","author":"Ahuja L.G.","year":"2019","unstructured":"Ahuja L.G.; Taylor S.S.; Kornev A.P.; Tuning the &#x201C;violin&#x201D; of protein kinases: The role of dynamics-based allostery. IUBMB Life 2019,71(6),685-696","journal-title":"IUBMB Life"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"660","DOI":"10.2174\/138161210790883732","volume":"16","author":"Govoni S.","year":"2010","unstructured":"Govoni S.; Amadio M.; Battaini F.; Pascale A.; Senescence of the brain: Focus on cognitive kinases. Curr Pharm Des 2010,16(6),660-671","journal-title":"Curr Pharm Des"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1134\/S0006297917030026","volume":"82","author":"Borodinova A.A.","year":"2017","unstructured":"Borodinova A.A.; Zuzina A.B.; Balaban P.M.; Role of atypical protein kinases in maintenance of long-term memory and synaptic plasticity. Biochemistry (Mosc) 2017,82(3),243-256","journal-title":"Biochemistry (Mosc)"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.neubiorev.2014.06.012","volume":"50","author":"van der Zee E.A.","year":"2015","unstructured":"van der Zee E.A.; Synapses, spines and kinases in mammalian learning and memory, and the impact of aging. Neurosci Biobehav Rev 2015,50,77-85","journal-title":"Neurosci Biobehav Rev"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.3390\/ijms20133131","volume":"20","author":"Kim N.","year":"2019","unstructured":"Kim N.; Chen D.; Zhou X.Z.; Lee T.H.; Death-associated protein kinase 1 phosphorylation in neuronal cell death and neurodegenerative disease. Int J Mol Sci 2019,20,3131","journal-title":"Int J Mol Sci"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.biopsych.2017.06.004","volume":"83","author":"Nygaard H.B.","year":"2018","unstructured":"Nygaard H.B.; Targeting Fyn Kinase in Alzheimer\u2019s Disease. Biol Psychiatry 2018,83(4),369-376","journal-title":"Biol Psychiatry"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.neuron.2014.12.007","volume":"85","author":"Pickrell A.M.","year":"2015","unstructured":"Pickrell A.M.; Youle R.J.; The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson\u2019s disease. Neuron 2015,85(2),257-273","journal-title":"Neuron"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.pharmthera.2018.09.010","volume":"194","author":"Arbones M.L.","year":"2019","unstructured":"Arbones M.L.; Thomazeau A.; Nakano-Kobayashi A.; Hagiwara M.; Delabar J.M.; DYRK1A and cognition: A lifelong relationship. Pharmacol Ther 2019,194,199-221","journal-title":"Pharmacol Ther"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3390\/brainsci8100187","volume":"8","author":"Feki A.","year":"2018","unstructured":"Feki A.; Hibaoui Y.; DYRK1A protein, a promising therapeutic target to improve cognitive deficits in down syndrome. Brain Sci 2018,8(10),8","journal-title":"Brain Sci"},{"key":"ref=10","first-page":"1","volume":"62","author":"Becker W.","year":"1999","unstructured":"Becker W.; Joost H.G.; Structural and functional characteristics of Dyrk, a novel subfamily of protein kinases with dual specificity. Prog Nucleic Acid Res Mol Biol 1999,62,1-17","journal-title":"Prog Nucleic Acid Res Mol Biol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.nbd.2019.02.022","volume":"127","author":"Arranz J.","year":"2019","unstructured":"Arranz J.; Balducci E.; Arat&#xF3; K.; S&#xE1;nchez-Elexpuru G.; Najas S.; Parras A.; Rebollo E.; Pijuan I.; Erb I.; Verde G.; Sahun I.; Barallobre M.J.; Lucas J.J.; S&#xE1;nchez M.P.; de la Luna S.; Arbon&#xE9;s M.L.; Impaired development of neocortical circuits contributes to the neurological alterations in DYRK1A haploinsufficiency syndrome. Neurobiol Dis 2019,127,210-222","journal-title":"Neurobiol Dis"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1080\/01677063.2018.1438427","volume":"32","author":"Shaikh M.N.","year":"2018","unstructured":"Shaikh M.N.; Tejedor F.J.; Mnb\/Dyrk1A orchestrates a transcriptional network at the transition from self-renewing neurogenic progenitors to postmitotic neuronal precursors. J Neurogenet 2018,32(1),37-50","journal-title":"J Neurogenet"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/s41598-017-00682-y","volume":"7","author":"Yin X.","year":"2017","unstructured":"Yin X.; Jin N.; Shi J.; Zhang Y.; Wu Y.; Gong C.X.; Iqbal K.; Liu F.; Dyrk1A overexpression leads to increase of 3R-tau expression and cognitive deficits in Ts65Dn Down syndrome mice. Sci Rep 2017,7(1),619","journal-title":"Sci Rep"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"3195","DOI":"10.1007\/s12035-020-01967-6","volume":"57","author":"Fructuoso M.","year":"2020","unstructured":"Fructuoso M.; Gu Y.C.; Kassis N.; de Lagran M.M.; Dierssen M.; Janel N.; Ethanol-induced changes in brain of transgenic mice overexpressing DYRK1A. Mol Neurobiol 2020,57(7),3195-3205","journal-title":"Mol Neurobiol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1002\/jnr.24560","volume":"98","author":"Li W.","year":"2020","unstructured":"Li W.; Pozzo-Miller L.; Dysfunction of the corticostriatal pathway in autism spectrum disorders. J Neurosci Res 2020,98(11),2130-2147","journal-title":"J Neurosci Res"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"104268","DOI":"10.1016\/j.yexmp.2019.104268","volume":"110","author":"Qui&#xF1;ones-Lombra&#xF1;a A.","year":"2019","unstructured":"Qui&#xF1;ones-Lombra&#xF1;a A.; Blanco J.G.; Comparative analysis of the DYRK1A-SRSF6-TNNT2 pathway in myocardial tissue from individuals with and without Down syndrome. Exp Mol Pathol 2019,110,104268","journal-title":"Exp Mol Pathol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1021\/acsmedchemlett.0c00346","volume":"11","author":"Kargbo R.B.","year":"2020","unstructured":"Kargbo R.B.; Selective DYRK1A inhibitor for the treatment of neurodegenerative diseases: Alzheimer, Parkinson, Huntington, and Down Syndrome. ACS Med Chem Lett 2020,11(10),1795-1796","journal-title":"ACS Med Chem Lett"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/ene.13439","volume":"25","author":"Lane C.A.","year":"2018","unstructured":"Lane C.A.; Hardy J.; Schott J.M.; Alzheimer\u2019s disease. Eur J Neurol 2018,25(1),59-70","journal-title":"Eur J Neurol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1038\/d41586-018-05717-6","volume":"559","author":"Hodson R.","year":"2018","unstructured":"Hodson R.; Alzheimer\u2019s disease. Nature 2018,559(7715),S1","journal-title":"Nature"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.jalz.2017.09.011","volume":"14","author":"An Y.","year":"2018","unstructured":"An Y.; Varma V.R.; Varma S.; Casanova R.; Dammer E.; Pletnikova O.; Chia C.W.; Egan J.M.; Ferrucci L.; Troncoso J.; Levey A.I.; Lah J.; Seyfried N.T.; Legido-Quigley C.; O\u2019Brien R.; Thambisetty M.; Evidence for brain glucose dysregulation in Alzheimer\u2019s disease. Alzheimers Dement 2018,14(3),318-329","journal-title":"Alzheimers Dement"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/547153a","volume":"547","author":"McDade E.","year":"2017","unstructured":"McDade E.; Bateman R.J.; Stop Alzheimer\u2019s before it starts. Nature 2017,547(7662),153-155","journal-title":"Nature"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"5541","DOI":"10.2147\/IJN.S200490","volume":"14","author":"Tiwari S.","year":"2019","unstructured":"Tiwari S.; Atluri V.; Kaushik A.; Yndart A.; Nair M.; Alzheimer\u2019s disease: Pathogenesis, diagnostics, and therapeutics. Int J Nanomedicine 2019,14,5541-5554","journal-title":"Int J Nanomedicine"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/978-981-32-9358-8_16","volume":"Vol. 1184","author":"Gallardo G.","year":"2019","unstructured":"Gallardo G.; Holtzman D.M.; Amyloid-&#x3B2; and tau at the crossroads of Alzheimer\u2019s disease. Advances in Experimental Medicine and Biology 2019,Vol. 1184,187-203","journal-title":"Advances in Experimental Medicine and Biology"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1517\/13543784.15.1.1","volume":"15","author":"Martinez A.","year":"2006","unstructured":"Martinez A.; Castro A.; Novel cholinesterase inhibitors as future effective drugs for the treatment of Alzheimer\u2019s disease. Expert Opin Investig Drugs 2006,15(1),1-12","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2174\/1570159X13666150716165726","volume":"14","author":"Ferreira-Vieira T.H.","year":"2016","unstructured":"Ferreira-Vieira T.H.; Guimaraes I.M.; Silva F.R.; Ribeiro F.M.; Alzheimer\u2019s disease: Targeting the cholinergic system. Curr Neuropharmacol 2016,14(1),101-115","journal-title":"Curr Neuropharmacol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"446","DOI":"10.3389\/fnins.2019.00446","volume":"13","author":"Chen X.Q.","year":"2019","unstructured":"Chen X.Q.; Mobley W.C.; Exploring the pathogenesis of Alzheimer disease in basal forebrain cholinergic neurons: Converging insights from alternative hypotheses. Front Neurosci 2019,13,446","journal-title":"Front Neurosci"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3390\/biom10010040","volume":"10","author":"Stanciu G.D.","year":"2019","unstructured":"Stanciu G.D.; Luca A.; Rusu R.N.; Bild V.; Beschea Chiriac S.I.; Solcan C.; Bild W.; Ababei D.C.; Alzheimer\u2019s disease pharmacotherapy in relation to cholinergic system involvement. Biomolecules 2019,10(1),40","journal-title":"Biomolecules"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ejmech.2017.07.070","volume":"139","author":"Jouanne M.","year":"2017","unstructured":"Jouanne M.; Rault S.; Voisin-Chiret A.S.; Tau protein aggregation in Alzheimer\u2019s disease: An attractive target for the development of novel therapeutic agents. Eur J Med Chem 2017,139,153-167","journal-title":"Eur J Med Chem"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.nbd.2005.03.020","volume":"20","author":"Ferrer I.","year":"2005","unstructured":"Ferrer I.; Barrachina M.; Puig B.; Mart&#xED;nez de Lagr&#xE1;n M.; Mart&#xED; E.; Avila J.; Dierssen M.; Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models. Neurobiol Dis 2005,20(2),392-400","journal-title":"Neurobiol Dis"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1515\/revneuro-2017-0006","volume":"28","author":"Kozlov S.","year":"2017","unstructured":"Kozlov S.; Afonin A.; Evsyukov I.; Bondarenko A.; Alzheimer\u2019s disease: As it was in the beginning. Rev Neurosci 2017,28(8),825-843","journal-title":"Rev Neurosci"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"456","DOI":"10.3389\/fimmu.2020.00456","volume":"11","author":"Hampel H.","year":"2020","unstructured":"Hampel H.; Caraci F.; Cuello A.C.; Caruso G.; Nistic&#xF2; R.; Corbo M.; Baldacci F.; Toschi N.; Garaci F.; Chiesa P.A.; Verdooner S.R.; Akman-Anderson L.; Hern&#xE1;ndez F.; &#xC1;vila J.; Emanuele E.; Valenzuela P.L.; Luc&#xED;a A.; Watling M.; Imbimbo B.P.; Vergallo A.; Lista S.; A path toward precision medicine for neuroinflammatory mechanisms in Alzheimer\u2019s disease. Front Immunol 2020,11,456","journal-title":"Front Immunol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41577-019-0262-0","volume":"20","author":"Colonna M.","year":"2020","unstructured":"Colonna M.; Brioschi S.; Neuroinflammation and neurodegeneration in human brain at single-cell resolution. Nat Rev Immunol 2020,20(2),81-82","journal-title":"Nat Rev Immunol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/imcb.12301","volume":"98","author":"Webers A.","year":"2020","unstructured":"Webers A.; Heneka M.T.; Gleeson P.A.; The role of innate immune responses and neuroinflammation in amyloid accumulation and progression of Alzheimer\u2019s disease. Immunol Cell Biol 2020,98(1),28-41","journal-title":"Immunol Cell Biol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/jnc.13411","volume":"136","author":"Minter M.R.","year":"2016","unstructured":"Minter M.R.; Taylor J.M.; Crack P.J.; The contribution of neuroinflammation to amyloid toxicity in Alzheimer\u2019s disease. J Neurochem 2016,136(3),457-474","journal-title":"J Neurochem"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"89ra57","DOI":"10.1126\/scitranslmed.3002156","volume":"3","author":"Castellano J.M.","year":"2011","unstructured":"Castellano J.M.; Kim J.; Stewart F.R.; Jiang H.; DeMattos R.B.; Patterson B.W.; Fagan A.M.; Morris J.C.; Mawuenyega K.G.; Cruchaga C.; Goate A.M.; Bales K.R.; Paul S.M.; Bateman R.J.; Holtzman D.M.; Human apoE isoforms differentially regulate brain amyloid-&#x3B2; peptide clearance. Sci Transl Med 2011,3(89),89ra57","journal-title":"Sci Transl Med"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"E1807","DOI":"10.1073\/pnas.1220484110","volume":"110","author":"Verghese P.B.","year":"2013","unstructured":"Verghese P.B.; Castellano J.M.; Garai K.; Wang Y.; Jiang H.; Shah A.; Bu G.; Frieden C.; Holtzman D.M.; Apo E.; ApoE influences amyloid-&#x3B2; (A&#x3B2;) clearance despite minimal apoE\/A&#x3B2; association in physiological conditions. Proc Natl Acad Sci USA 2013,110(19),E1807-E1816","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/349704a0","volume":"349","author":"Goate A.","year":"1991","unstructured":"Goate A.; Chartier-Harlin M.C.; Mullan M.; Brown J.; Crawford F.; Fidani L.; Giuffra L.; Haynes A.; Irving N.; James L.; Mant R.; Newton P.; Rooke K.; Roques P.; Talbot C.; Pericak-Vance M.; Roses A.; Williamson R.; Rossor M.; Owen M.; Hardy J.; Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer\u2019s disease. Nature 1991,349(6311),704-706","journal-title":"Nature"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1038\/375754a0","volume":"375","author":"Sherrington R.","year":"1995","unstructured":"Sherrington R.; Rogaev E.I.; Liang Y.; Rogaeva E.A.; Levesque G.; Ikeda M.; Chi H.; Lin C.; Li G.; Holman K.; Tsuda T.; Mar L.; Foncin J.F.; Bruni A.C.; Montesi M.P.; Sorbi S.; Rainero I.; Pinessi L.; Nee L.; Chumakov I.; Pollen D.; Brookes A.; Sanseau P.; Polinsky R.J.; Wasco W.; Da Silva H.A.R.; Haines J.L.; Perkicak-Vance M.A.; Tanzi R.E.; Roses A.D.; Fraser P.E.; Rommens J.M.; St George-Hyslop P.H.; Cloning of a gene bearing missense mutations in early-onset familial Alzheimer\u2019s disease. Nature 1995,375(6534),754-760","journal-title":"Nature"},{"key":"ref=39","first-page":"970","volume":"269","author":"Levy-Lahad E.","year":"1995","unstructured":"Levy-Lahad E.; Wijsman E.M.; Nemens E.; Anderson L.; Goddard K.A.B.; Weber J.L.; Bird T.D.; Schellenberg G.D.; A familial Alzheimer\u2019s disease locus on chromosome. iScience 1995,269,970-973","journal-title":"iScience"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/376775a0","volume":"376","author":"Rogaev E.I.","year":"1995","unstructured":"Rogaev E.I.; Sherrington R.; Rogaeva E.A.; Levesque G.; Ikeda M.; Liang Y.; Chi H.; Lin C.; Holman K.; Tsuda T.; Mar L.; Sorbi S.; Nacmias B.; Piacentini S.; Amaducci L.; Chumakov I.; Cohen D.; Lannfelt L.; Fraser P.E.; Rommens J.M.; George-Hyslop P.H.S.; Familial Alzheimer\u2019s disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer\u2019s disease type 3 gene. Nature 1995,376(6543),775-778","journal-title":"Nature"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.biopsych.2014.05.006","volume":"77","author":"Karch C.M.","year":"2015","unstructured":"Karch C.M.; Goate A.M.; Alzheimer\u2019s disease risk genes and mechanisms of disease pathogenesis. Biol Psychiatry 2015,77(1),43-51","journal-title":"Biol Psychiatry"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1590\/1980-57642016dn11-020002","volume":"11","author":"de Nazareth A.M.","year":"2017","unstructured":"de Nazareth A.M.; Type 2 diabetes mellitus in the pathophysiology of Alzheimer\u2019s disease. Dement Neuropsychol 2017,11(2),105-113","journal-title":"Dement Neuropsychol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1093\/toxsci\/kfy025","volume":"163","author":"Hsu H.W.","year":"2018","unstructured":"Hsu H.W.; Bondy S.C.; Kitazawa M.; Environmental and dietary exposure to copper and its cellular mechanisms linking to Alzheimer\u2019s disease. Toxicol Sci 2018,163(2),338-345","journal-title":"Toxicol Sci"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"267","DOI":"10.14336\/AD.2016.1017","volume":"8","author":"Banerjee A.","year":"2017","unstructured":"Banerjee A.; Khemka V.K.; Roy D.; Dhar A.; Sinha Roy T.K.; Biswas A.; Mukhopadhyay B.; Chakrabarti S.; Role of pro-inflammatory cytokines and vitamin D in probable Alzheimer\u2019s disease with depression. Aging Dis 2017,8(3),267-276","journal-title":"Aging Dis"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"87","DOI":"10.5114\/fn.2019.85929","volume":"57","author":"A. Armstrong R.","year":"2019","unstructured":"A. Armstrong R.; Risk factors for Alzheimer\u2019s disease. Folia Neuropathol 2019,57(2),87-105","journal-title":"Folia Neuropathol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12929-019-0524-y","volume":"26","author":"Silva M.V.F.","year":"2019","unstructured":"Silva M.V.F.; Loures C.M.G.; Alves L.C.V.; de Souza L.C.; Borges K.B.G.; Carvalho M.D.G.; Alzheimer\u2019s disease: Risk factors and potentially protective measures. J Biomed Sci 2019,26(1),33","journal-title":"J Biomed Sci"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/0896-6273(95)90286-4","volume":"14","author":"Tejedor F.","year":"1995","unstructured":"Tejedor F.; Zhu X.R.; Kaltenbach E.; Ackermann A.; Baumann A.; Canal I.; Heisenberg M.; Fischbach K.F.; Pongs O.; minibrain: A new protein kinase family involved in postembryonic neurogenesis in Drosophila. Neuron 1995,14(2),287-301","journal-title":"Neuron"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"6116","DOI":"10.1038\/s41598-017-06440-4","volume":"7","author":"Mozzi A.","year":"2017","unstructured":"Mozzi A.; Forni D.; Cagliani R.; Pozzoli U.; Clerici M.; Sironi M.; Distinct selective forces and Neanderthal introgression shaped genetic diversity at genes involved in neurodevelopmental disorders. Sci Rep 2017,7(1),6116","journal-title":"Sci Rep"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1006\/geno.1996.0636","volume":"38","author":"Song W.J.","year":"1996","unstructured":"Song W.J.; Sternberg L.R.; Kasten-Sport&#xE8;s C.; Keuren M.L.; Chung S.H.; Slack A.C.; Miller D.E.; Glover T.W.; Chiang P.W.; Lou L.; Kurnit D.M.; Isolation of human and murine homologues of the Drosophila minibrain gene: Human homologue maps to 21q22.2 in the Down syndrome &#x201C;critical region&#x201D;. Genomics 1996,38(3),331-339","journal-title":"Genomics"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21186906","volume":"21","author":"Mart&#xED;nez-Cu&#xE9; C.","year":"2020","unstructured":"Mart&#xED;nez-Cu&#xE9; C.; Rueda N.; Signalling pathways implicated in Alzheimer\u2019s disease neurodegeneration in individuals with and without Down Syndrome. Int J Mol Sci 2020,21(18),1-36","journal-title":"Int J Mol Sci"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1242\/dev.066167","volume":"138","author":"H&#xE4;mmerle B.","year":"2011","unstructured":"H&#xE4;mmerle B.; Ulin E.; Guimera J.; Becker W.; Guillemot F.; Tejedor F.J.; Transient expression of Mnb\/Dyrk1a couples cell cycle exit and differentiation of neuronal precursors by inducing p27KIP1 expression and suppressing NOTCH signaling. Development 2011,138(12),2543-2554","journal-title":"Development"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1046\/j.1460-9568.2003.02665.x","volume":"17","author":"H&#xE4;mmerle B.","year":"2003","unstructured":"H&#xE4;mmerle B.; Carnicero A.; Elizalde C.; Ceron J.; Mart&#xED;nez S.; Tejedor F.J.; Expression patterns and subcellular localization of the Down syndrome candidate protein MNB\/DYRK1A suggest a role in late neuronal differentiation. Eur J Neurosci 2003,17(11),2277-2286","journal-title":"Eur J Neurosci"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/j.1742-4658.2010.07954.x","volume":"278","author":"Tejedor F.J.","year":"2011","unstructured":"Tejedor F.J.; H&#xE4;mmerle B.; MNB\/DYRK1A as a multiple regulator of neuronal development. FEBS J 2011,278(2),223-235","journal-title":"FEBS J"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"3235","DOI":"10.1007\/s00018-009-0123-2","volume":"66","author":"Park J.","year":"2009","unstructured":"Park J.; Song W.J.; Chung K.C.; Function and regulation of Dyrk1A: Towards understanding Down syndrome. Cell Mol Life Sci 2009,66(20),3235-3240","journal-title":"Cell Mol Life Sci"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"100245","DOI":"10.1074\/jbc.RA120.015574","volume":"296","author":"Lee Y.H.","year":"2021","unstructured":"Lee Y.H.; Im, E.; Hyun, M.; Park, J.; Chung, K.C. Protein phosphatase PPM1B inhibits DYRK1A kinase through dephosphorylation of pS258 and reduces toxic tau aggregation. J Biol Chem 2021,296,100245","journal-title":"J Biol Chem"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1016\/S0140-6736(20)30689-9","volume":"395","author":"Fortea J.","year":"2020","unstructured":"Fortea J.; Vilaplana E.; Carmona-Iragui M.; Benejam B.; Videla L.; Barroeta I.; Fern&#xE1;ndez S.; Altuna M.; Pegueroles J.; Montal V.; Valldeneu S.; Gim&#xE9;nez S.; Gonz&#xE1;lez-Ortiz S.; Mu&#xF1;oz L.; Estell&#xE9;s T.; Ill&#xE1;n-Gala I.; Belbin O.; Camacho V.; Wilson L.R.; Annus T.; Osorio R.S.; Videla S.; Lehmann S.; Holland A.J.; Alcolea D.; Clarim&#xF3;n J.; Zaman S.H.; Blesa R.; Lle&#xF3; A.; Clinical and biomarker changes of Alzheimer\u2019s disease in adults with Down syndrome: A cross-sectional study. Lancet 2020,395(10242),1988-1997","journal-title":"Lancet"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1002\/dneu.22709","volume":"79","author":"Carmona-Iragui M.","year":"2019","unstructured":"Carmona-Iragui M.; Videla L.; Lle&#xF3; A.; Fortea J.; Down syndrome, Alzheimer disease, and cerebral amyloid angiopathy: The complex triangle of brain amyloidosis. Dev Neurobiol 2019,79(7),716-737","journal-title":"Dev Neurobiol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"3224","DOI":"10.1096\/fj.07-104539","volume":"22","author":"Liu F.","year":"2008","unstructured":"Liu F.; Liang Z.; Wegiel J.; Hwang Y.W.; Iqbal K.; Grundke-Iqbal I.; Ramakrishna N.; Gong C.X.; Overexpression of Dyrk1A contributes to neurofibrillary degeneration in Down syndrome. FASEB J 2008,22(9),3224-3233","journal-title":"FASEB J"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"34850","DOI":"10.1074\/jbc.M707358200","volume":"282","author":"Ryoo S.R.","year":"2007","unstructured":"Ryoo S.R.; Jeong H.K.; Radnaabazar C.; Yoo J.J.; Cho H.J.; Lee H.W.; Kim I.S.; Cheon Y.H.; Ahn Y.S.; Chung S.H.; Song W.J.; DYRK1A-mediated hyperphosphorylation of Tau. A functional link between Down syndrome and Alzheimer disease. J Biol Chem 2007,282(48),34850-34857","journal-title":"J Biol Chem"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/jnc.13018","volume":"133","author":"Coutadeur S.","year":"2015","unstructured":"Coutadeur S.; Benyamine H.; Delalonde L.; de Oliveira C.; Leblond B.; Foucourt A.; Besson T.; Casagrande A.S.; Taverne T.; Girard A.; Pando M.P.; D&#xE9;sir&#xE9; L.; A novel DYRK1A (dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer\u2019s disease: Effect on Tau and amyloid pathologies in vitro. J Neurochem 2015,133(3),440-451","journal-title":"J Neurochem"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"e425","DOI":"10.1038\/tp.2014.61","volume":"4","author":"Janel N.","year":"2014","unstructured":"Janel N.; Sarazin M.; Corlier F.; Corne H.; de Souza L.C.; Hamelin L.; Aka A.; Lagarde J.; Blehaut H.; Hindi&#xE9; V.; Rain J.C.; Arbones M.L.; Dubois B.; Potier M.C.; Bottlaender M.; Delabar J.M.; Plasma DYRK1A as a novel risk factor for Alzheimer\u2019s disease. Transl Psychiatry 2014,4(8),e425","journal-title":"Transl Psychiatry"},{"key":"ref=62","first-page":"6","volume":"2020","author":"Delabar J.M.","year":"2020","unstructured":"Delabar J.M.; Ortner M.; Simon S.; Wijkhuisen A.; Feraudet-Tarisse C.; Pegon J.; Vidal E.; Hirschberg Y.; Dubois B.; Potier M.C.; Altered age-linked regulation of plasma DYRK1A in elderly cognitive complainers (INSIGHT-PreAD Study) with high brain amyloid load. Alzheimer\u2019s Dement Transl Res Clin Interv 2020,2020,6","journal-title":"Alzheimer\u2019s Dement Transl Res Clin Interv"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"311","DOI":"10.3233\/JAD-2010-1221","volume":"19","author":"Murphy M.P.","year":"2010","unstructured":"Murphy M.P.; LeVine H.; Alzheimer\u2019s disease and the amyloid-&#x3B2; peptide. J Alzheimers Dis 2010,19(1),311-323","journal-title":"J Alzheimers Dis"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1111\/bpa.12717","volume":"29","author":"Paasila P.J.","year":"2019","unstructured":"Paasila P.J.; Davies D.S.; Kril J.J.; Goldsbury C.; Sutherland G.T.; The relationship between the morphological subtypes of microglia and Alzheimer\u2019s disease neuropathology. Brain Pathol 2019,29(6),726-740","journal-title":"Brain Pathol"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.brainresbull.2019.01.004","volume":"146","author":"Madav Y.","year":"2019","unstructured":"Madav Y.; Wairkar S.; Prabhakar B.; Recent therapeutic strategies targeting beta amyloid and tauopathies in Alzheimer\u2019s disease. Brain Res Bull 2019,146,171-184","journal-title":"Brain Res Bull"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.freeradbiomed.2020.08.030","volume":"160","author":"Lee H.J.","year":"2020","unstructured":"Lee H.J.; Woo H.; Lee H.E.; Jeon H.; Ryu K.Y.; Nam J.H.; Jeon S.G.; Park H.; Lee J.S.; Han K.M.; Lee S.M.; Kim J.; Kang R.J.; Lee Y.H.; Kim J.I.; Hoe H.S.; The novel DYRK1A inhibitor KVN93 regulates cognitive function, amyloid-beta pathology, and neuroinflammation. Free Radic Biol Med 2020,160,575-595","journal-title":"Free Radic Biol Med"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.arr.2012.06.003","volume":"12","author":"Martin L.","year":"2013","unstructured":"Martin L.; Latypova X.; Wilson C.M.; Magnaudeix A.; Perrin M.L.; Yardin C.; Terro F.; Tau protein kinases: Involvement in Alzheimer\u2019s disease. Ageing Res Rev 2013,12(1),289-309","journal-title":"Ageing Res Rev"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1111\/j.1742-4658.2010.07955.x","volume":"278","author":"Wegiel J.","year":"2011","unstructured":"Wegiel J.; Gong C.X.; Hwang Y.W.; The role of DYRK1A in neurodegenerative diseases. FEBS J 2011,278(2),236-245","journal-title":"FEBS J"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/bs.apcsb.2016.07.001","volume":"105","author":"Kay L.J.","year":"2016","unstructured":"Kay L.J.; Smulders-Srinivasan T.K.; Soundararajan M.; Understanding the multifaceted role of human Down Syndrome kinase DYRK1A. Adv Protein Chem Struct Biol 2016,105,127-171","journal-title":"Adv Protein Chem Struct Biol"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1590\/0001-3765201420130333","volume":"86","author":"Lagunes T.","year":"2014","unstructured":"Lagunes T.; Herrera-Rivero M.; Hern&#xE1;ndez-Aguilar M.E.; Aranda-Abreu G.; Abeta(1-42) Induces abnormal alternative splicing of tau exons 2\/3 in NGF-Induced PC12 cells. An Acad Bras Cienc 2014,86(4),1927-1934","journal-title":"An Acad Bras Cienc"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.ejmech.2018.08.093","volume":"158","author":"Pathak A.","year":"2018","unstructured":"Pathak A.; Rohilla A.; Gupta T.; Akhtar M.J.; Haider M.R.; Sharma K.; Haider K.; Yar M.S.; DYRK1A kinase inhibition with emphasis on neurodegeneration: A comprehensive evolution story-cum-perspective. Eur J Med Chem 2018,158,559-592","journal-title":"Eur J Med Chem"},{"key":"ref=72","first-page":"11","volume":"2010","author":"Azorsa D.O.","year":"2010","unstructured":"Azorsa D.O.; Robeson R.L.H.; Frost D.; hoovet, B.M.; Brautigam, G.R.; Dickey, C.; Beaudry, C.; Basu, G.D.; Holz, D.R.; Hernandez, J.A.; Bisanz, K.M.; Gwinn, L.; Grover, A.; Rogers, J.; Reiman, E.M.; Hutton, M.; Stephan, D.A.; Mousses, S.; Dunckley, T. High-Content SiRNA screening of the kinome identifies Kinases involved in Alzheimer\u2019s Disease-related Tau Hyperphosphorylation. BMC Genomics 2010,2010,11","journal-title":"BMC Genomics"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1111\/acel.12648","volume":"16","author":"Branca C.","year":"2017","unstructured":"Branca C.; Shaw D.M.; Belfiore R.; Gokhale V.; Shaw A.Y.; Foley C.; Smith B.; Hulme C.; Dunckley T.; Meechoovet B.; Caccamo A.; Oddo S.; Dyrk1 inhibition improves Alzheimer\u2019s disease-like pathology. Aging Cell 2017,16(5),1146-1154","journal-title":"Aging Cell"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.nbd.2017.06.010","volume":"106","author":"Garc&#xED;a-Cerro S.","year":"2017","unstructured":"Garc&#xED;a-Cerro S.; Rueda N.; Vidal V.; Lantigua S.; Mart&#xED;nez-Cu&#xE9; C.; Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues several Alzheimer\u2019s disease phenotypes. Neurobiol Dis 2017,106,76-88","journal-title":"Neurobiol Dis"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1093\/brain\/awy132","volume":"141","author":"Hampel H.","year":"2018","unstructured":"Hampel H.; Mesulam M.M.; Cuello A.C.; Farlow M.R.; Giacobini E.; Grossberg G.T.; Khachaturian A.S.; Vergallo A.; Cavedo E.; Snyder P.J.; Khachaturian Z.S.; The cholinergic system in the pathophysiology and treatment of Alzheimer\u2019s disease. Brain 2018,141(7),1917-1933","journal-title":"Brain"},{"key":"ref=76","doi-asserted-by":"crossref","first-page":"5789","DOI":"10.3390\/molecules25245789","volume":"25","author":"Breijyeh Z.","year":"2020","unstructured":"Breijyeh Z.; Karaman R.; Comprehensive review on Alzheimer\u2019s disease: Causes and treatment. Molecules 2020,25,5789","journal-title":"Molecules"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.expneurol.2012.10.016","volume":"239","author":"Hijazi M.","year":"2013","unstructured":"Hijazi M.; Fillat C.; Medina J.M.; Velasco A.; Overexpression of DYRK1A inhibits choline acetyltransferase induction by oleic acid in cellular models of Down syndrome. Exp Neurol 2013,239,229-234","journal-title":"Exp Neurol"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.2174\/1567205014666170203141717","volume":"14","author":"Regen F.","year":"2017","unstructured":"Regen F.; Hellmann-Regen J.; Costantini E.; Reale M.; Neuroinflammation and Alzheimer\u2019s disease: Implications for microglial activation. Curr Alzheimer Res 2017,14(11),1140-1148","journal-title":"Curr Alzheimer Res"},{"key":"ref=79","doi-asserted-by":"crossref","first-page":"8751","DOI":"10.3390\/ijms21228751","volume":"21","author":"S&#xE1;nchez-Saras&#xFA;a S.","year":"2020","unstructured":"S&#xE1;nchez-Saras&#xFA;a S.; Fern&#xE1;ndez-P&#xE9;rez I.; Espinosa-Fern&#xE1;ndez V.; S&#xE1;nchez-P&#xE9;rez A.M.; Ledesma J.C.; Can we treat neuroinflammation in Alzheimer\u2019s disease? Int J Mol Sci 2020,21,8751","journal-title":"Int J Mol Sci"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"4784268","DOI":"10.1155\/2018\/4784268","volume":"2018","author":"Gelders G.","year":"2018","unstructured":"Gelders G.; Baekelandt V.; Van der Perren A.; Linking neuroinflammation and neurodegeneration in Parkinson\u2019s disease. J Immunol Res 2018,2018,4784268","journal-title":"J Immunol Res"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0165-5728(97)00204-X","volume":"85","author":"Jeohn G-H.","year":"1998","unstructured":"Jeohn G-H.; Kong L-Y.; Wilson B.; Hudson P.; Hong J-S.; Synergistic neurotoxic effects of combined treatments with cytokines in murine primary mixed neuron\/glia cultures. J Neuroimmunol 1998,85(1),1-10","journal-title":"J Neuroimmunol"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"e19264","DOI":"10.1371\/journal.pone.0019264","volume":"6","author":"Frost D.","year":"2011","unstructured":"Frost D.; Meechoovet B.; Wang T.; Gately S.; Giorgetti M.; Shcherbakova I.; Dunckley T.; &#x3B2;-carboline compounds, including harmine, inhibit DYRK1A and tau phosphorylation at multiple Alzheimer\u2019s disease-related sites. PLoS One 2011,6(5),e19264","journal-title":"PLoS One"},{"key":"ref=83","doi-asserted-by":"crossref","first-page":"870","DOI":"10.2174\/1567205014666170317113606","volume":"14","author":"Domingues C.","year":"2017","unstructured":"Domingues C.; da Cruz e Silva, O.A.B.; Henriques, A.G. Impact of Cytokines and Chemokines on Alzheimer\u2019s Disease neuropathological hallmarks. Curr Alzheimer Res 2017,14(8),870-882","journal-title":"Curr Alzheimer Res"},{"key":"ref=84","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s10787-019-00580-x","volume":"27","author":"Kaur D.","year":"2019","unstructured":"Kaur D.; Sharma V.; Deshmukh R.; Activation of microglia and astrocytes: A roadway to neuroinflammation and Alzheimer\u2019s disease. Inflammopharmacology 2019,27,663-677","journal-title":"Inflammopharmacology"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.bj.2018.01.003","volume":"41","author":"Laurent C.","year":"2018","unstructured":"Laurent C.; Bu&#xE9;e L.; Blum D.; Tau and neuroinflammation: What impact for Alzheimer\u2019s Disease and Tauopathies? Biomed J 2018,41(1),21-33","journal-title":"Biomed J"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"570045","DOI":"10.3389\/fnmol.2020.570045","volume":"13","author":"Michalicova A.","year":"2020","unstructured":"Michalicova A.; Majerova P.; Kovac A.; Tau protein and its role in blood-brain barrier dysfunction. Front Mol Neurosci 2020,13,570045","journal-title":"Front Mol Neurosci"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"5424","DOI":"10.1002\/hbm.24782","volume":"40","author":"Chandra A.","year":"2019","unstructured":"Chandra A.; Valkimadi P-E.; Pagano G.; Cousins O.; Dervenoulas G.; Politis M.; Applications of amyloid, tau, and neuroinflammation PET imaging to Alzheimer\u2019s disease and mild cognitive impairment. Hum Brain Mapp 2019,40(18),5424-5442","journal-title":"Hum Brain Mapp"},{"key":"ref=88","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13024-016-0142-z","volume":"12","author":"Leyns C.E.G.","year":"2017","unstructured":"Leyns C.E.G.; Holtzman D.M.; Glial contributions to neurodegeneration in tauopathies. Mol Neurodegener 2017,12,1-16","journal-title":"Mol Neurodegener"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"e13000","DOI":"10.1111\/acel.13000","volume":"18","author":"Melchior B.","year":"2019","unstructured":"Melchior B.; Mittapalli G.K.; Lai C.; Duong-Polk K.; Stewart J.; G&#xFC;ner B.; Hofilena B.; Tjitro A.; Anderson S.D.; Herman D.S.; Dellamary L.; Swearingen C.J.; Sunil K.C.; Yazici Y.; Tau pathology reduction with SM07883, a novel, potent, and selective oral DYRK1A inhibitor: A potential therapeutic for Alzheimer\u2019s disease. Aging Cell 2019,18(5),e13000","journal-title":"Aging Cell"},{"key":"ref=90","doi-asserted-by":"crossref","first-page":"3085756","DOI":"10.1155\/2019\/3085756","volume":"2019","author":"Moldogazieva N.T.","year":"2019","unstructured":"Moldogazieva N.T.; Mokhosoev I.M.; Oxidative stress and advanced lipoxidation and glycation end products (ALEs and AGEs) in aging and age-related diseases. Oxid Med Cell Longev 2019,2019,3085756","journal-title":"Oxid Med Cell Longev"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.redox.2017.10.014","volume":"14","author":"Cheignon C.","year":"2018","unstructured":"Cheignon C.; Tomas M.; Bonnefont-Rousselot D.; Faller P.; Hureau C.; Collin F.; Oxidative stress and the amyloid beta peptide in Alzheimer\u2019s disease. Redox Biol 2018,14,450-464","journal-title":"Redox Biol"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"151979","DOI":"10.1155\/2015\/151979","volume":"2015","author":"Alavi Naini S.M.","year":"2015","unstructured":"Alavi Naini S.M.; Soussi-Yanicostas N.; Tau hyperphosphorylation and oxidative stress, a critical vicious circle in neurodegenerative tauopathies? Oxid Med Cell Longev 2015,2015,151979","journal-title":"Oxid Med Cell Longev"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1080\/13543776.2017.1360285","volume":"27","author":"Nguyen T.L.","year":"2017","unstructured":"Nguyen T.L.; Fruit C.; H&#xE9;rault Y.; Meijer L.; Besson T.; Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: A survey of recent patent literature. Expert Opin Ther Pat 2017,27(11),1183-1199","journal-title":"Expert Opin Ther Pat"},{"key":"ref=94","first-page":"2232","volume":"13","author":"Sebastiani G.","year":"2021","unstructured":"Sebastiani G.; Almeida-Toledano L.; Serra-Delgado M.; Navarro-Tapia E.; Sailer S.; Valverde O.; Garcia-Algar O.; Andreu-Fern&#xE1;ndez V.; Therapeutic effects of catechins in less common neurological and neurodegenerative disorders. Nutr 2021,13,2232","journal-title":"Nutr"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.nbd.2013.08.008","volume":"60","author":"Pons-Espinal M.","year":"2013","unstructured":"Pons-Espinal M.; Martinez de Lagran M.; Dierssen M.; Environmental enrichment rescues DYRK1A activity and hippocampal adult neurogenesis in TgDyrk1A. Neurobiol Dis 2013,60,18-31","journal-title":"Neurobiol Dis"},{"key":"ref=96","doi-asserted-by":"crossref","first-page":"681","DOI":"10.4155\/fmc-2016-0013","author":"Stotani Silvia","year":"2016","unstructured":"Stotani Silvia; Giordanetto Fabrizio; Medda Federico; DYRK1A inhibition as potential treatment for Alzheimer\u2019s disease. Future Med Chem 2016,681-696","journal-title":"Future Med Chem"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/cmdc.201600539","volume":"12","author":"B&#xE1;lint B.","year":"2017","unstructured":"B&#xE1;lint B.; W&#xE9;ber C.; Cruzalegui F.; Burbridge M.; Kotschy A.; Structure-based design and synthesis of harmine derivatives with different selectivity profiles in kinase versus monoamine oxidase inhibition. ChemMedChem 2017,12(12),932-939","journal-title":"ChemMedChem"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/ncomms1090","volume":"1","author":"Ogawa Y.","year":"2010","unstructured":"Ogawa Y.; Nonaka Y.; Goto T.; Ohnishi E.; Hiramatsu T.; Kii I.; Yoshida M.; Ikura T.; Onogi H.; Shibuya H.; Hosoya T.; Ito N.; Hagiwara M.; Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A. Nat Commun 2010,1(1),86","journal-title":"Nat Commun"},{"key":"ref=99","year":"2019","unstructured":"Centre, cambridge crystallographic data (org.). In: GOLD User Guide; 2019"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"113554","DOI":"10.1016\/j.ejmech.2021.113554","volume":"222","author":"Liu W.","year":"2021","unstructured":"Liu W.; Liu X.; Tian L.; Gao Y.; Liu W.; Chen H.; Jiang X.; Xu Z.; Ding H.; Zhao Q.; Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3&#x3B2;\/DYRK1A dual inhibitors for the treatment of Alzheimer\u2019s disease. Eur J Med Chem 2021,222,113554","journal-title":"Eur J Med Chem"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867329666220620162018","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/206225\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867329666220620162018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T11:56:17Z","timestamp":1693655777000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/206225\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":100,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867329666220620162018","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-12-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-22","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}